Literature DB >> 22383801

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.

Lishomwa C Ndhlovu1, Sandra Lopez-Vergès, Jason D Barbour, R Brad Jones, Aashish R Jha, Brian R Long, Eric C Schoeffler, Tsuyoshi Fujita, Douglas F Nixon, Lewis L Lanier.   

Abstract

Natural killer (NK) cells are innate lymphocytes that play an important role against viral infections and cancer. This effect is achieved through a complex mosaic of inhibitory and activating receptors expressed by NK cells that ultimately determine the magnitude of the NK-cell response. The T-cell immunoglobulin- and mucin domain-containing (Tim)-3 receptor was initially identified as a T-helper 1-specific type I membrane protein involved in regulating T-cell responses. Human NK cells transcribe the highest amounts of Tim-3 among lymphocytes. Tim-3 protein is expressed on essentially all mature CD56(dim)CD16(+) NK cells and is expressed heterogeneously in the immature CD56(bright)CD16(-) NK-cell subset in blood from healthy adults and in cord blood. Tim-3 expression was induced on CD56(bright)CD16(-) NK cells after stimulation with IL-15 or IL-12 and IL-18 in vitro, suggesting that Tim-3 is a maturation marker on NK cells. Whereas Tim-3 has been used to identify dysfunctional T cells, NK cells expressing high amounts of Tim-3 are fully responsive with respect to cytokine production and cytotoxicity. However, when Tim-3 was cross-linked with antibodies it suppressed NK cell-mediated cytotoxicity. These findings suggest that NK-cell responses may be negatively regulated when NK cells encounter target cells expressing cognate ligands of Tim-3.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22383801      PMCID: PMC3335380          DOI: 10.1182/blood-2011-11-392951

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

Authors:  Cyril Fauriat; Eric O Long; Hans-Gustaf Ljunggren; Yenan T Bryceson
Journal:  Blood       Date:  2009-12-01       Impact factor: 22.113

2.  Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors.

Authors:  Shiki Takamura; Sachiyo Tsuji-Kawahara; Hideo Yagita; Hisaya Akiba; Mayumi Sakamoto; Tomomi Chikaishi; Maiko Kato; Masaaki Miyazawa
Journal:  J Immunol       Date:  2010-03-29       Impact factor: 5.422

Review 3.  SLAM-family receptors: immune regulators with or without SAP-family adaptors.

Authors:  André Veillette
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

4.  T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B.

Authors:  Ying Ju; Nan Hou; Jing Meng; Xiaoyan Wang; Xiaoning Zhang; Di Zhao; Ying Liu; Faliang Zhu; Lining Zhang; Wensheng Sun; Xiaohong Liang; Lifen Gao; Chunhong Ma
Journal:  J Hepatol       Date:  2010-01-06       Impact factor: 25.083

5.  T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells.

Authors:  Rosemarie H DeKruyff; Xia Bu; Angela Ballesteros; César Santiago; Yee-Ling E Chim; Hyun-Hee Lee; Piia Karisola; Muriel Pichavant; Gerardo G Kaplan; Dale T Umetsu; Gordon J Freeman; José M Casasnovas
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

Review 6.  The costimulatory role of TIM molecules.

Authors:  Roselynn Rodriguez-Manzanet; Rosemarie DeKruyff; Vijay K Kuchroo; Dale T Umetsu
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

7.  Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation.

Authors:  Masafumi Nakayama; Hisaya Akiba; Kazuyoshi Takeda; Yuko Kojima; Masaaki Hashiguchi; Miyuki Azuma; Hideo Yagita; Ko Okumura
Journal:  Blood       Date:  2009-02-17       Impact factor: 22.113

8.  CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.

Authors:  Jianhua Yu; Hsiaoyin C Mao; Min Wei; Tiffany Hughes; Jianying Zhang; Il-kyoo Park; Shujun Liu; Susan McClory; Guido Marcucci; Rossana Trotta; Michael A Caligiuri
Journal:  Blood       Date:  2009-11-06       Impact factor: 22.113

9.  TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines.

Authors:  William D Hastings; David E Anderson; Nasim Kassam; Ken Koguchi; Edward A Greenfield; Sally C Kent; Xin Xiao Zheng; Terry B Strom; David A Hafler; Vijay K Kuchroo
Journal:  Eur J Immunol       Date:  2009-09       Impact factor: 5.532

10.  HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complications.

Authors:  Lishomwa C Ndhlovu; Fabio E Leal; Aaron M Hasenkrug; Aashish R Jha; Karina I Carvalho; Ijeoma G Eccles-James; Fernanda R Bruno; Raphaella G S Vieira; Vanessa A York; Glen M Chew; R Brad Jones; Yuetsu Tanaka; Walter K Neto; Sabri S Sanabani; Mario A Ostrowski; Aluisio C Segurado; Douglas F Nixon; Esper G Kallas
Journal:  PLoS Negl Trop Dis       Date:  2011-04-26
View more
  173 in total

1.  IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma.

Authors:  Joe-Marc Chauvin; Mignane Ka; Ornella Pagliano; Carmine Menna; Quanquan Ding; Richelle DeBlasio; Cindy Sanders; Jiajie Hou; Xian-Yang Li; Soldano Ferrone; Diwakar Davar; John M Kirkwood; Robert J Johnston; Alan J Korman; Mark J Smyth; Hassane M Zarour
Journal:  Clin Cancer Res       Date:  2020-06-26       Impact factor: 12.531

Review 2.  Natural killer cell memory in infection, inflammation and cancer.

Authors:  Adelheid Cerwenka; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2016-01-25       Impact factor: 53.106

3.  Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.

Authors:  Melissa A Geller; David A Knorr; David A Hermanson; Lee Pribyl; Laura Bendzick; Valarie McCullar; Jeffrey S Miller; Dan S Kaufman
Journal:  Cytotherapy       Date:  2013-10       Impact factor: 5.414

4.  Effect of the use of Galectin-9 and blockade of TIM-3 receptor in the latent cellular reservoir of HIV-1.

Authors:  Marta Sanz; Nadia Madrid-Elena; Sergio Serrano-Villar; Alejandro Vallejo; Carolina Gutiérrez; Santiago Moreno
Journal:  J Virol       Date:  2020-12-23       Impact factor: 5.103

5.  Interaction of TIM4 and TIM3 induces T helper 1 cell apoptosis.

Authors:  Rong-Ti Ge; Lu Zeng; Li-Hua Mo; Ling-Zhi Xu; Huan-Ping Zhang; Hai-Qiong Yu; Min Zhang; Zhi-Gang Liu; Zhan-Ju Liu; Ping-Chang Yang
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

6.  Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Authors:  Ila Datar; Miguel F Sanmamed; Jun Wang; Brian S Henick; Jungmin Choi; Ti Badri; Weilai Dong; Nikita Mani; Maria Toki; Luis D Mejías; Maria D Lozano; Jose Luis Perez-Gracia; Vamsidhar Velcheti; Matthew D Hellmann; Justin F Gainor; Kristen McEachern; David Jenkins; Konstantinos Syrigos; Katerina Politi; Scott Gettinger; David L Rimm; Roy S Herbst; Ignacio Melero; Lieping Chen; Kurt A Schalper
Journal:  Clin Cancer Res       Date:  2019-05-03       Impact factor: 12.531

Review 7.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

Review 8.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 9.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.